{
 "name": "Psilocybin and psychedelic research in Seattle and Washington: a register",
 "description": "Research programs, clinical trials with a Washington site and published psilocybin studies by Seattle-area institutions, with registry IDs, PubMed IDs and status.",
 "publisher": "Magic Mushrooms Seattle",
 "url": "https://magicmushroomsseattle.org/seattle-psilocybin-research",
 "license": "CC BY 4.0",
 "license_url": "https://creativecommons.org/licenses/by/4.0/",
 "updated": "2026-11-02",
 "record_count": 58,
 "source_note": "Trial records come from ClinicalTrials.gov and studies from PubMed; status is as listed on the date checked.",
 "records": [
  {
   "kind": "program",
   "title": "Psilocybin Therapy Services Pilot Program (2SSB 5263)",
   "institution": "University of Washington Department of Psychiatry and Behavioral Sciences",
   "year": 2023,
   "condition": "PTSD, mood disorders or substance use disorders, in populations including first responders and veterans aged 21 and older",
   "status": "In law since July 23, 2023; carried out through PsiloStudy",
   "finding": "Chapter 364, Laws of 2023, signed with a partial veto on May 9, 2023, requires UW, subject to appropriation, to offer psilocybin therapy through FDA-approved pathways by January 1, 2025, with outreach to groups less likely to be included in research.",
   "id": "Chapter 364, Laws of 2023",
   "url": "https://lawfilesext.leg.wa.gov/biennium/2023-24/Pdf/Bills/Session%20Laws/Senate/5263-S2.SL.pdf",
   "anchor": "sb-5263-pilot"
  },
  {
   "kind": "program",
   "title": "State budget 2023-25: UW psilocybin appropriation",
   "institution": "Washington Legislature, appropriated to the University of Washington",
   "year": 2023,
   "condition": "",
   "status": "Enacted May 16, 2023; unchanged in the 2024 supplemental budget",
   "finding": "$1,464,000 from the workforce education investment account, provided solely for implementation of 2SSB 5263 (the provisos do not name PsiloStudy).",
   "id": "ESSB 5187, Sec. 606(85)",
   "url": "https://lawfilesext.leg.wa.gov/biennium/2023-24/Pdf/Bills/Session%20Laws/Senate/5187-S.SL.pdf",
   "anchor": "budget-2023-25-psilocybin"
  },
  {
   "kind": "program",
   "title": "State budget 2025-27: UW psilocybin appropriation",
   "institution": "Washington Legislature, appropriated to the University of Washington",
   "year": 2025,
   "condition": "",
   "status": "Enacted May 20, 2025; unchanged in the 2026 supplemental budget (ESSB 5998)",
   "finding": "$730,000 from the workforce education investment account, provided solely for implementation of chapter 364, Laws of 2023 (psilocybin).",
   "id": "ESSB 5167, Sec. 606(50)",
   "url": "https://lawfilesext.leg.wa.gov/biennium/2025-26/Pdf/Bills/Session%20Laws/Senate/5167-S.SL.pdf",
   "anchor": "budget-2025-27-psilocybin"
  },
  {
   "kind": "program",
   "title": "UW Center for Novel Therapeutics in Addiction Psychiatry (NTAP)",
   "institution": "University of Washington Department of Psychiatry and Behavioral Sciences",
   "year": 2023,
   "condition": "Alcohol, opioid and tobacco use disorders",
   "status": "Official UW research center as of a March 30, 2023 announcement; UW's Addictions, Drug and Alcohol Institute announced on February 2, 2026 that NTAP had joined it",
   "finding": "Studies psychedelic compounds combined with behavioral interventions for addiction; runs the state-mandated PsiloStudy and was named in the 2024 budget for the state's ibogaine study money; director Nathan Sackett.",
   "id": "NTAP",
   "url": "https://ntap.psychiatry.uw.edu/about-us/news-events/news/center-for-novel-therapeutics-in-addiction-psychiatry-is-official",
   "anchor": "uw-ntap"
  },
  {
   "kind": "program",
   "title": "State funding for an initial UW study of ibogaine-assisted therapy",
   "institution": "University of Washington Center for Novel Therapeutics in Addiction Psychiatry",
   "year": 2024,
   "condition": "Ibogaine-assisted therapy (the budget text names no condition)",
   "status": "Appropriated March 29, 2024; no ClinicalTrials.gov record found",
   "finding": "$250,000 from the opioid abatement settlement account, provided solely for an initial study of ibogaine-assisted therapy.",
   "id": "ESSB 5950, Sec. 602(103)",
   "url": "https://lawfilesext.leg.wa.gov/biennium/2023-24/Pdf/Bills/Session%20Laws/Senate/5950-S.SL.pdf",
   "anchor": "ibogaine-funding-2024"
  },
  {
   "kind": "program",
   "title": "State funding for a UW cohort study of ibogaine-assisted therapy",
   "institution": "University of Washington",
   "year": 2025,
   "condition": "Opioid use disorder in adults",
   "status": "Appropriated May 20, 2025; unchanged in the 2026 supplemental; no ClinicalTrials.gov record found",
   "finding": "$10,000 for a prospective, randomized cohort study between July 1, 2025 and June 30, 2027 comparing ibogaine-assisted therapy at a licensed clinic in North America, followed by structured support, with treatment as usual; UW may also use private philanthropic funding.",
   "id": "ESSB 5167, Sec. 606(62)",
   "url": "https://lawfilesext.leg.wa.gov/biennium/2025-26/Pdf/Bills/Session%20Laws/Senate/5167-S.SL.pdf",
   "anchor": "ibogaine-funding-2025-27"
  },
  {
   "kind": "program",
   "title": "Washington Psilocybin Task Force final report",
   "institution": "Washington State Health Care Authority with the Center for Evidence-based Policy (OHSU)",
   "year": 2023,
   "condition": "Research gaps for UW and WSU",
   "status": "Final report delivered December 1, 2023",
   "finding": "Set up under 2SSB 5263; ranked research gaps for state-funded work, with racial diversity of trial participants first among population gaps, then people with co-occurring conditions, then larger samples.",
   "id": "Task force report, 2023",
   "url": "https://www.hca.wa.gov/assets/program/psilocybin-task-force-leg-report-2023.pdf",
   "anchor": "psilocybin-task-force"
  },
  {
   "kind": "trial",
   "title": "PsiloStudy: psilocybin with psychological support for veterans and first responders with PTSD and alcohol use disorder",
   "institution": "University of Washington Center for Novel Therapeutics in Addiction Psychiatry; site in Seattle",
   "year": 2025,
   "condition": "PTSD with alcohol use disorder in military veterans and first responders",
   "status": "Active, not recruiting",
   "finding": "Phase 2, single site, randomized, double-blind and placebo-controlled, with an open-label extension; about 40 participants aged 21 to 65 planned; primary outcome is safety; primary completion estimated November 1, 2026.",
   "id": "NCT06853912",
   "url": "https://clinicaltrials.gov/study/NCT06853912",
   "anchor": "psilostudy"
  },
  {
   "kind": "trial",
   "title": "PIVOT: psilocybin for veterans with treatment-resistant depression",
   "institution": "VA Office of Research and Development; site at VA Puget Sound, Seattle",
   "year": 2026,
   "condition": "Treatment-resistant depression in veterans, with or without PTSD",
   "status": "Recruiting",
   "finding": "Phase 3 randomized controlled trial at five VA sites; 240 participants planned; Seattle site recruiting; primary completion estimated December 2, 2030.",
   "id": "NCT07226232",
   "url": "https://clinicaltrials.gov/study/NCT07226232",
   "anchor": "pivot-va-psilocybin"
  },
  {
   "kind": "trial",
   "title": "Psilocybin therapy for frontline clinicians with depression after COVID-19 work",
   "institution": "University of Washington; site in Seattle",
   "year": 2022,
   "condition": "Depression and burnout in doctors, advanced practice clinicians and nurses",
   "status": "Completed",
   "finding": "Randomized trial (registry lists phase 3) of psilocybin with psychotherapy against an active placebo; 30 enrolled; results posted on the registry and published in JAMA Network Open (PMID 39636638).",
   "id": "NCT05163496",
   "url": "https://clinicaltrials.gov/study/NCT05163496",
   "anchor": "frontline-clinician-trial"
  },
  {
   "kind": "trial",
   "title": "Group retreat psilocybin therapy for cancer-related anxiety (phase 1/2)",
   "institution": "University of Washington; site at Fred Hutch/University of Washington Cancer Consortium, Seattle",
   "year": 2023,
   "condition": "Anxiety in people with metastatic cancer",
   "status": "Completed",
   "finding": "Phase 1/2 group-retreat study; 55 started and 52 completed; registry results list 3 participants with serious adverse events and no instances of unattended psilocybin-related distress.",
   "id": "NCT05847686",
   "url": "https://clinicaltrials.gov/study/NCT05847686",
   "anchor": "group-retreat-cancer-phase-1-2"
  },
  {
   "kind": "trial",
   "title": "Second group psilocybin retreat for partial responders with cancer-related anxiety",
   "institution": "University of Washington; site at Fred Hutch/University of Washington Cancer Consortium, Seattle",
   "year": 2024,
   "condition": "Anxiety in people with metastatic cancer who partly responded to a first retreat",
   "status": "Completed",
   "finding": "Phase 1 single-arm study; 15 enrolled; completed September 30, 2025; published in 2026 (PMID 42058096).",
   "id": "NCT06644170",
   "url": "https://clinicaltrials.gov/study/NCT06644170",
   "anchor": "second-retreat-trial"
  },
  {
   "kind": "trial",
   "title": "Group retreat psilocybin therapy for anxiety and depression in metastatic or incurable cancer (phase 2a)",
   "institution": "University of Washington; site at Fred Hutch/University of Washington Cancer Consortium, Seattle",
   "year": 2026,
   "condition": "Anxiety and depression with metastatic solid tumors or incurable blood cancers",
   "status": "Active, not recruiting",
   "finding": "Phase 2a group-retreat study; 16 enrolled; primary completion estimated December 1, 2026; the record says the psilocybin is provided by Filament Health.",
   "id": "NCT07336238",
   "url": "https://clinicaltrials.gov/study/NCT07336238",
   "anchor": "group-retreat-cancer-phase-2a"
  },
  {
   "kind": "trial",
   "title": "Group retreat psilocybin therapy for clinicians with loss of meaning in their work and depression",
   "institution": "University of Washington; no site listed yet",
   "year": 2026,
   "condition": "Depression and loss of meaning in work among healthcare clinicians",
   "status": "Not yet recruiting",
   "finding": "Phase 2 sequential study of preparation for group retreat therapy; 72 participants planned; start estimated for June 2026, but the record, last updated May 4, 2026, still lists the study as not yet recruiting and names no site.",
   "id": "NCT07565909",
   "url": "https://clinicaltrials.gov/study/NCT07565909",
   "anchor": "clinician-group-retreat-trial"
  },
  {
   "kind": "trial",
   "title": "COMP360 psilocybin, two administrations, for treatment-resistant depression",
   "institution": "COMPASS Pathways; site in Seattle (Seattle Neuropsychiatric Treatment Center)",
   "year": 2023,
   "condition": "Treatment-resistant depression",
   "status": "Active, not recruiting",
   "finding": "Phase 3, multicenter, randomized, double-blind and controlled; 572 enrolled across 116 sites; primary completion November 13, 2025; no results posted on the registry as of November 2, 2026.",
   "id": "NCT05711940",
   "url": "https://clinicaltrials.gov/study/NCT05711940",
   "anchor": "comp360-two-administrations"
  },
  {
   "kind": "trial",
   "title": "COMP360 psilocybin, single administration, for treatment-resistant depression",
   "institution": "COMPASS Pathways; site in Everett (Core Clinical Research)",
   "year": 2023,
   "condition": "Treatment-resistant depression",
   "status": "Completed",
   "finding": "Phase 3, multicenter, randomized, double-blind and placebo-controlled; 258 enrolled across 40 sites; completed April 15, 2026; no results posted on the registry as of November 2, 2026.",
   "id": "NCT05624268",
   "url": "https://clinicaltrials.gov/study/NCT05624268",
   "anchor": "comp360-single-administration"
  },
  {
   "kind": "trial",
   "title": "uAspire: psilocybin for major depressive disorder",
   "institution": "Usona Institute; sites in Bellevue and Vancouver, WA",
   "year": 2024,
   "condition": "Major depressive disorder",
   "status": "Active, not recruiting",
   "finding": "Phase 3, randomized, double-blind, multicenter; 238 enrolled across 29 sites; primary completion January 5, 2026; study completion estimated January 30, 2027.",
   "id": "NCT06308653",
   "url": "https://clinicaltrials.gov/study/NCT06308653",
   "anchor": "usona-uaspire"
  },
  {
   "kind": "trial",
   "title": "EMBRACE: CYB003, a deuterated psilocin analog, for major depressive disorder",
   "institution": "Cybin IRL Limited; sites in Seattle and Everett",
   "year": 2025,
   "condition": "Major depressive disorder",
   "status": "Recruiting",
   "finding": "Phase 3, multicenter, double-blind, randomized; compares two dose levels of CYB003 with placebo; 330 planned across 79 sites; Seattle site recruiting, Everett site not yet recruiting.",
   "id": "NCT06793397",
   "url": "https://clinicaltrials.gov/study/NCT06793397",
   "anchor": "cybin-cyb003-embrace"
  },
  {
   "kind": "trial",
   "title": "Psilocybin-enhanced psychotherapy for methamphetamine use disorder",
   "institution": "Portland VA Research Foundation; site at the Portland VA campus in Vancouver, WA",
   "year": 2022,
   "condition": "Methamphetamine use disorder",
   "status": "Active, not recruiting",
   "finding": "Phase 1/2 single-site study; 30 participants planned; primary completion estimated December 31, 2026.",
   "id": "NCT04982796",
   "url": "https://clinicaltrials.gov/study/NCT04982796",
   "anchor": "psilocybin-methamphetamine-vancouver"
  },
  {
   "kind": "trial",
   "title": "MDMA-assisted therapy for pathological narcissism",
   "institution": "University of Washington; site in Seattle",
   "year": 2024,
   "condition": "Pathological narcissism",
   "status": "Active, not recruiting",
   "finding": "Early phase 1, open-label pilot; 12 enrolled; primary completion was estimated for August 15, 2026, and the record was last updated in February 2026.",
   "id": "NCT06565494",
   "url": "https://clinicaltrials.gov/study/NCT06565494",
   "anchor": "mdma-narcissism-trial"
  },
  {
   "kind": "trial",
   "title": "Group-MVP: group MDMA therapy for veterans with PTSD",
   "institution": "Portland VA Research Foundation; site at the Portland-Vancouver VA, Vancouver, WA",
   "year": 2023,
   "condition": "PTSD in veterans",
   "status": "Completed",
   "finding": "Phase 1/2 open-label feasibility and safety study; 23 enrolled; completed March 14, 2025.",
   "id": "NCT05961527",
   "url": "https://clinicaltrials.gov/study/NCT05961527",
   "anchor": "group-mdma-veterans"
  },
  {
   "kind": "trial",
   "title": "SM-001, an ayahuasca-type plant decoction, in healthy adults",
   "institution": "Advanced Integrative Medical Science (AIMS) Institute; site in Seattle",
   "year": 2023,
   "condition": "Healthy adults (the record also lists major depression and PTSD)",
   "status": "Unknown",
   "finding": "Phase 1 open-label study; 12 participants planned; start estimated for October 2023; the record has not been updated since July 2023, so whether the study ran is not known.",
   "id": "NCT05894902",
   "url": "https://clinicaltrials.gov/study/NCT05894902",
   "anchor": "aims-sm-001"
  },
  {
   "kind": "trial",
   "title": "Voyage: DT120 (LSD) for generalized anxiety disorder",
   "institution": "Definium Therapeutics US, Inc.; site in Seattle (Seattle Neuropsychiatric Treatment Center)",
   "year": 2024,
   "condition": "Generalized anxiety disorder",
   "status": "Active, not recruiting",
   "finding": "Phase 3, randomized, double-blind, placebo-controlled 12-week study with a 40-week open-label extension; 214 enrolled across 34 sites; the registry lists MM120 and lysergide tartrate among the drug's other names.",
   "id": "NCT06741228",
   "url": "https://clinicaltrials.gov/study/NCT06741228",
   "anchor": "dt120-voyage"
  },
  {
   "kind": "trial",
   "title": "Panorama: MM120 (LSD) for generalized anxiety disorder",
   "institution": "Definium Therapeutics US, Inc.; site in Everett (Core Clinical Research)",
   "year": 2025,
   "condition": "Generalized anxiety disorder",
   "status": "Active, not recruiting",
   "finding": "Phase 3, randomized, double-blind, placebo-controlled 12-week study with a 40-week open-label extension; 245 enrolled across 36 sites; primary completion August 13, 2026.",
   "id": "NCT06809595",
   "url": "https://clinicaltrials.gov/study/NCT06809595",
   "anchor": "mm120-panorama"
  },
  {
   "kind": "trial",
   "title": "Ascend: DT120 (LSD) for major depressive disorder",
   "institution": "Definium Therapeutics US, Inc.; sites in Seattle and Vancouver, WA",
   "year": 2026,
   "condition": "Major depressive disorder",
   "status": "Recruiting",
   "finding": "Phase 3, randomized, double-blind, placebo-controlled 12-week study with a 40-week open-label extension; 165 planned across 30 sites; both Washington sites listed as not yet recruiting.",
   "id": "NCT07592689",
   "url": "https://clinicaltrials.gov/study/NCT07592689",
   "anchor": "dt120-ascend"
  },
  {
   "kind": "trial",
   "title": "ELUMINA: VLS-01 buccal film for treatment-resistant depression",
   "institution": "atai Therapeutics; site in Bellevue (Seattle Neuropsychiatric Treatment Center)",
   "year": 2024,
   "condition": "Treatment-resistant depression",
   "status": "Completed",
   "finding": "Phase 2, multicenter, randomized, double-blind, placebo-controlled with repeated administrations; 142 enrolled across 48 sites; completed October 16, 2026. The developer describes VLS-01 as a DMT film; the registry record does not name the compound.",
   "id": "NCT06524830",
   "url": "https://clinicaltrials.gov/study/NCT06524830",
   "anchor": "vls-01-elumina"
  },
  {
   "kind": "trial",
   "title": "RE104 for postpartum depression",
   "institution": "Reunion Neuroscience; site in Seattle",
   "year": 2024,
   "condition": "Postpartum depression",
   "status": "Completed",
   "finding": "Phase 2, multicenter, randomized, double-blind, dose-controlled; 84 enrolled across 38 sites; completed June 16, 2025. The developer describes RE104 (luvesilocin) as a prodrug of 4-OH-DiPT, a 5-HT2A agonist; the registry record does not name the compound.",
   "id": "NCT06342310",
   "url": "https://clinicaltrials.gov/study/NCT06342310",
   "anchor": "re104-postpartum"
  },
  {
   "kind": "trial",
   "title": "RE104 for adjustment disorder in cancer and other medical illness",
   "institution": "Reunion Neuroscience; site in Seattle (Seattle Neuropsychiatric Treatment Center)",
   "year": 2025,
   "condition": "Adjustment disorder in people with cancer or other medical illness",
   "status": "Recruiting",
   "finding": "Phase 2, randomized, double-blind, dose-controlled; 100 planned across 32 sites; Seattle site recruiting; primary completion estimated November 2026.",
   "id": "NCT07002034",
   "url": "https://clinicaltrials.gov/study/NCT07002034",
   "anchor": "re104-adjustment-disorder"
  },
  {
   "kind": "trial",
   "title": "IMPACT-2: methylone for PTSD",
   "institution": "Transcend Therapeutics; site in Bellevue (Seattle Neuropsychiatric Treatment Center)",
   "year": 2024,
   "condition": "PTSD",
   "status": "Completed",
   "finding": "Phase 2 study; 62 enrolled across 12 sites; completed September 23, 2025; results posted on the registry.",
   "id": "NCT06215261",
   "url": "https://clinicaltrials.gov/study/NCT06215261",
   "anchor": "methylone-impact-2"
  },
  {
   "kind": "trial",
   "title": "EMPOWER-1: TSND-201 (methylone) for PTSD",
   "institution": "Transcend Therapeutics; site in Seattle (Seattle Neuropsychiatric Treatment Center)",
   "year": 2026,
   "condition": "PTSD",
   "status": "Recruiting",
   "finding": "Phase 3, randomized, double-blind, placebo-controlled; 300 planned across 37 sites; Seattle site recruiting.",
   "id": "NCT07456696",
   "url": "https://clinicaltrials.gov/study/NCT07456696",
   "anchor": "tsnd-201-empower-1"
  },
  {
   "kind": "paper",
   "title": "Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial",
   "institution": "University of Washington",
   "year": 2024,
   "condition": "Depression in frontline clinicians after COVID-19 work",
   "status": "Published",
   "finding": "In a randomized trial of 30 US physicians, advanced practice clinicians and nurses, depression scores (MADRS) fell 21.3 points with psilocybin therapy versus 9.3 with a niacin placebo at day 28, a 12-point difference; the burnout difference was not statistically significant.",
   "id": "PMID 39636638",
   "url": "https://pubmed.ncbi.nlm.nih.gov/39636638/",
   "anchor": "back-2024-jama-network-open"
  },
  {
   "kind": "paper",
   "title": "Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study",
   "institution": "University of Washington and Fred Hutch Cancer Center",
   "year": 2026,
   "condition": "Anxiety and depression in metastatic cancer",
   "status": "Published",
   "finding": "Across eight group retreats with 52 participants, Fred Hutch's summary reports clinically meaningful drops in anxiety and depression that lasted at least six months and no unattended distress that needed the backup facilitators.",
   "id": "DOI 10.1177/28314425251413856",
   "url": "https://doi.org/10.1177/28314425251413856",
   "anchor": "back-2026-group-retreat-results"
  },
  {
   "kind": "paper",
   "title": "A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience",
   "institution": "University of Washington and Fred Hutch Cancer Center",
   "year": 2026,
   "condition": "Anxiety and depression in metastatic cancer (partial responders)",
   "status": "Published",
   "finding": "In a single-arm study, 13 partial responders completed a second group retreat; no serious adverse events occurred, mean HADS scores fell from 15.08 to 9.00 at day 8, and 69% reached scores below the clinical threshold.",
   "id": "PMID 42058096",
   "url": "https://pubmed.ncbi.nlm.nih.gov/42058096/",
   "anchor": "back-2026-second-retreat"
  },
  {
   "kind": "paper",
   "title": "Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy",
   "institution": "University of Washington and Fred Hutch Cancer Center",
   "year": 2024,
   "condition": "Facilitator touch in group psilocybin therapy",
   "status": "Published",
   "finding": "Methods report from the group cancer trial: the team rewrote its rules on facilitator touch after two unexpected touch-related experiences in the first three retreats.",
   "id": "PMID 40051480",
   "url": "https://pubmed.ncbi.nlm.nih.gov/40051480/",
   "anchor": "back-2024-touch-guidelines"
  },
  {
   "kind": "paper",
   "title": "Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study",
   "institution": "University of Washington and Fred Hutch Cancer Center",
   "year": 2025,
   "condition": "Facilitation model for group psilocybin therapy in metastatic cancer",
   "status": "Published",
   "finding": "Technical report with no new sample: describes the trial's facilitation model, built on the anthropology of rites of passage (preparation, the psilocybin session and integration).",
   "id": "PMID 42539893",
   "url": "https://pubmed.ncbi.nlm.nih.gov/42539893/",
   "anchor": "back-2025-rite-of-passage"
  },
  {
   "kind": "paper",
   "title": "Preparing the body for psilocybin therapy: receptive and generative interoception in cancer patients",
   "institution": "University of Washington",
   "year": 2026,
   "condition": "Body-focused preparation for psilocybin therapy in cancer",
   "status": "Published",
   "finding": "Hypothesis paper with no sample: proposes a framework for interoceptive preparation and a six-category taxonomy of bodily experiences reported in sessions.",
   "id": "PMID 42922907",
   "url": "https://pubmed.ncbi.nlm.nih.gov/42922907/",
   "anchor": "back-2026-interoception"
  },
  {
   "kind": "paper",
   "title": "What Psilocybin Taught Me About Dying",
   "institution": "University of Washington",
   "year": 2018,
   "condition": "Palliative care",
   "status": "Published",
   "finding": "Essay by UW palliative care physician Anthony Back, published online November 9, 2018 (print July 2019); no abstract and no sample.",
   "id": "PMID 30412005",
   "url": "https://pubmed.ncbi.nlm.nih.gov/30412005/",
   "anchor": "back-2018-essay"
  },
  {
   "kind": "paper",
   "title": "Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach",
   "institution": "University of Washington",
   "year": 2025,
   "condition": "Pathological narcissism",
   "status": "Published",
   "finding": "Theoretical paper with no sample: proposes psychoanalytically informed MDMA-assisted therapy for pathological narcissism, which the authors say is being tested in an investigator-initiated trial; UW pilot NCT06565494 lists both authors as principal investigators.",
   "id": "PMID 40256160",
   "url": "https://pubmed.ncbi.nlm.nih.gov/40256160/",
   "anchor": "albert-back-2025-narcissism"
  },
  {
   "kind": "paper",
   "title": "Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis",
   "institution": "Washington State University, Spokane, with UW's Center for Novel Therapeutics in Addiction Psychiatry",
   "year": 2024,
   "condition": "Underground psychedelic-assisted therapy practice",
   "status": "Published",
   "finding": "Qualitative analysis of interviews with underground guides (the abstract gives no count) found four themes, including mixed feelings about legalization: wanting more access but worrying about losing flexibility.",
   "id": "PMID 40051684",
   "url": "https://pubmed.ncbi.nlm.nih.gov/40051684/",
   "anchor": "smith-2024-underground-guides"
  },
  {
   "kind": "paper",
   "title": "Ibogaine for Opioid Use Disorder: An Unrecognized Risk",
   "institution": "Co-authored by Nathan Sackett, the name of UW's NTAP director (the PubMed record lists no affiliations)",
   "year": 2026,
   "condition": "Ibogaine and opioid use disorder",
   "status": "Published",
   "finding": "Commentary with no sample: warns that presenting ibogaine as a replacement for methadone or buprenorphine could raise overdose risk for some people with opioid use disorder.",
   "id": "PMID 41535993",
   "url": "https://pubmed.ncbi.nlm.nih.gov/41535993/",
   "anchor": "terasaki-2026-ibogaine"
  },
  {
   "kind": "paper",
   "title": "Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review",
   "institution": "International authors including UW's Nathan Sackett",
   "year": 2026,
   "condition": "Negative and depressive symptoms in schizophrenia spectrum disorders",
   "status": "Published",
   "finding": "Narrative review with no new sample of mechanistic, animal and early clinical evidence on whether psychedelics could help these symptoms.",
   "id": "PMID 41830808",
   "url": "https://pubmed.ncbi.nlm.nih.gov/41830808/",
   "anchor": "sabe-2026-schizophrenia-review"
  },
  {
   "kind": "paper",
   "title": "Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder",
   "institution": "University of Washington School of Medicine",
   "year": 2023,
   "condition": "Cannabis use disorder",
   "status": "Published",
   "finding": "Systematic review screened 305 unique records and found one primary study, using ketamine, that met its inclusion criteria.",
   "id": "PMID 37435402",
   "url": "https://pubmed.ncbi.nlm.nih.gov/37435402/",
   "anchor": "phan-terry-2023-cannabis"
  },
  {
   "kind": "paper",
   "title": "Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the \"high-risk\" addiction patient",
   "institution": "University of Washington Department of Psychiatry and Behavioral Sciences",
   "year": 2023,
   "condition": "Access to psychedelic therapy for people with addiction",
   "status": "Published",
   "finding": "Ethics paper with no sample: argues for equitable access to psychedelic therapy for addiction patients labeled \"high-risk\".",
   "id": "PMID 37799400",
   "url": "https://pubmed.ncbi.nlm.nih.gov/37799400/",
   "anchor": "black-2023-lifeboat-ethics"
  },
  {
   "kind": "paper",
   "title": "Mania following use of ibogaine: A case series",
   "institution": "University of Washington Department of Psychiatry and Behavioral Sciences (co-author)",
   "year": 2015,
   "condition": "Mania after unregulated ibogaine use",
   "status": "Published",
   "finding": "Case series of 3 psychiatric emergency patients with no prior bipolar diagnosis who developed mania after unregulated ibogaine use; the authors call it the first report of mania stemming from ibogaine use.",
   "id": "PMID 25877487",
   "url": "https://pubmed.ncbi.nlm.nih.gov/25877487/",
   "anchor": "marta-2015-ibogaine-mania"
  },
  {
   "kind": "paper",
   "title": "Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks",
   "institution": "Cornell University, with co-authors at the Allen Institute for Brain Science, Seattle",
   "year": 2025,
   "condition": "Psilocybin and brain networks in mice",
   "status": "Published",
   "finding": "In mice (group sizes are in the paper, not the abstract), psilocybin rewired inputs to frontal cortex neurons in a network-specific way, and silencing a brain region during the drug session disrupted the rewiring.",
   "id": "PMID 41352354",
   "url": "https://pubmed.ncbi.nlm.nih.gov/41352354/",
   "anchor": "jiang-2025-cortical-rewiring"
  },
  {
   "kind": "paper",
   "title": "The void and the brain",
   "institution": "Allen Institute, Seattle",
   "year": 2025,
   "condition": "5-MeO-DMT and brain activity (EEG)",
   "status": "Published",
   "finding": "Commentary with no sample on an EEG study of inhaled 5-MeO-DMT that found strongly slowed brain activity without the alpha-power drop seen with other psychedelics.",
   "id": "PMID 40700015",
   "url": "https://pubmed.ncbi.nlm.nih.gov/40700015/",
   "anchor": "koch-2025-void"
  },
  {
   "kind": "paper",
   "title": "Psilocybin in Palliative Care: An Update",
   "institution": "Advanced Integrative Medical Science (AIMS) Institute, Seattle",
   "year": 2023,
   "condition": "Psilocybin in palliative care",
   "status": "Published",
   "finding": "Review with no new sample of five years of psilocybin evidence in palliative care; notes short follow-up and a risk of selection bias toward healthy, white, financially privileged people.",
   "id": "PMID 37305379",
   "url": "https://pubmed.ncbi.nlm.nih.gov/37305379/",
   "anchor": "whinkin-2023-palliative"
  },
  {
   "kind": "paper",
   "title": "A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State",
   "institution": "Washington State Patrol Toxicology Laboratory, Seattle",
   "year": 2015,
   "condition": "A death involving 25I-NBOMe and psilocin",
   "status": "Published",
   "finding": "Single-case review of a 2014 death of a 15-year-old after 25I-NBOMe and mushrooms; the manner of death was ruled accidental, from combined 25I-NBOMe and psilocin intoxication.",
   "id": "PMID 26378143",
   "url": "https://pubmed.ncbi.nlm.nih.gov/26378143/",
   "anchor": "lowe-2015-25i-nbome"
  },
  {
   "kind": "paper",
   "title": "Epidemiology of MDMA and associated club drugs in the Seattle area",
   "institution": "UW Alcohol and Drug Abuse Institute",
   "year": 2005,
   "condition": "MDMA and club drug use in the Seattle area",
   "status": "Published",
   "finding": "A review of seven Seattle-area data sources (surveys, deaths, emergency department mentions and treatment admissions) found moderate MDMA use, low death and acute harm, and high suspected adulteration.",
   "id": "PMID 16048818",
   "url": "https://pubmed.ncbi.nlm.nih.gov/16048818/",
   "anchor": "banta-green-2005-mdma"
  },
  {
   "kind": "paper",
   "title": "Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users' Patterns of Use and Perceived Effects",
   "institution": "Washington State University, Pullman",
   "year": 2025,
   "condition": "Patterns of psychedelic use",
   "status": "Published",
   "finding": "An online survey of 1,486 US adults who use psychedelics found MDMA, LSD, DMT and psilocybin were the most used, most use was recreational, and average distress ratings for acute effects were low.",
   "id": "PMID 39878200",
   "url": "https://pubmed.ncbi.nlm.nih.gov/39878200/",
   "anchor": "cuttler-2025-survey"
  },
  {
   "kind": "paper",
   "title": "Experimental Test of Perceptions of Psychedelics by Therapeutic and Recreational Use",
   "institution": "Washington State University Vancouver",
   "year": 2025,
   "condition": "Public perceptions of therapeutic and recreational psychedelic use",
   "status": "Published",
   "finding": "In an experiment with 309 participants, therapeutic use was seen as healthier than recreational use, and people with lifetime use rated both more positively.",
   "id": "PMID 39843984",
   "url": "https://pubmed.ncbi.nlm.nih.gov/39843984/",
   "anchor": "kiniry-2025-perceptions"
  },
  {
   "kind": "history",
   "title": "Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations",
   "institution": "University of Washington, Harborview Medical Center",
   "year": 1998,
   "condition": "Ketamine's psychedelic effects",
   "status": "Published",
   "finding": "In 10 healthy volunteers, ketamine's psychedelic effects rose in a straight line with blood level, and hallucinogen rating scores resembled those from an earlier DMT study.",
   "id": "PMID 9447860",
   "url": "https://pubmed.ncbi.nlm.nih.gov/9447860/",
   "anchor": "bowdle-1998-ketamine"
  },
  {
   "kind": "history",
   "title": "Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group",
   "institution": "Children's Hospital and Medical Center and University of Washington, Seattle",
   "year": 1992,
   "condition": "Amanita mushroom poisoning in children",
   "status": "Published",
   "finding": "Nine children were admitted for Amanita pantherina (8) or Amanita muscaria (1) poisoning; symptoms began within 30 to 180 minutes, 4 had seizures or twitching, and all recovered.",
   "id": "PMID 1347320",
   "url": "https://pubmed.ncbi.nlm.nih.gov/1347320/",
   "anchor": "benjamin-1992-amanita"
  },
  {
   "kind": "history",
   "title": "Psilocybin and psilocin levels in twenty species from seven genera of wild mushrooms in the Pacific Northwest, U.S.A.",
   "institution": "Michael W. Beug (longtime Evergreen State College chemistry teacher) and Jeremy Bigwood",
   "year": 1982,
   "condition": "Psilocybin in wild Pacific Northwest mushrooms",
   "status": "Published",
   "finding": "Of 20 wild species from seven genera tested, seven species from three genera contained psilocybin, and levels varied more than sevenfold between collections.",
   "id": "PMID 7201053",
   "url": "https://pubmed.ncbi.nlm.nih.gov/7201053/",
   "anchor": "beug-bigwood-1982"
  },
  {
   "kind": "history",
   "title": "Quantitative analysis of psilocybin and psilocin in Psilocybe baeocystis (Singer and Smith) by high-performance liquid chromatography and by thin-layer chromatography",
   "institution": "Michael W. Beug (longtime Evergreen State College chemistry teacher) and Jeremy Bigwood",
   "year": 1981,
   "condition": "Measuring psilocybin and psilocin in Psilocybe baeocystis",
   "status": "Published",
   "finding": "Method paper: rapid liquid chromatography and thin-layer chromatography measurement of psilocybin and psilocin in Psilocybe baeocystis.",
   "id": "PMID 7194879",
   "url": "https://pubmed.ncbi.nlm.nih.gov/7194879/",
   "anchor": "beug-bigwood-1981"
  },
  {
   "kind": "history",
   "title": "Second International Conference on Hallucinogenic Mushrooms, near Port Townsend",
   "institution": "Proceedings published by Madrona Publishers, Seattle",
   "year": 1977,
   "condition": "Hallucinogenic mushrooms of North America",
   "status": "Held October 27 to 30, 1977; extracts published 1978",
   "finding": "Extracts from the conference were published in Seattle in 1978 as Teonanácatl: Hallucinogenic Mushrooms of North America.",
   "id": "OCLC 4135392",
   "url": "https://search.worldcat.org/oclc/4135392",
   "anchor": "port-townsend-conference-1977"
  },
  {
   "kind": "history",
   "title": "Description and chemical analysis of a new species of hallucinogenic Psilocybe from the Pacific Northwest",
   "institution": "Gastón Guzmán and Jonathan Ott (affiliations not in the PubMed record)",
   "year": 1976,
   "condition": "A new Psilocybe species from the Pacific Northwest",
   "status": "Published",
   "finding": "Mycologia paper (November to December 1976 issue) that described a new hallucinogenic Psilocybe species from the Pacific Northwest and analyzed its chemistry.",
   "id": "PMID 1034878",
   "url": "https://pubmed.ncbi.nlm.nih.gov/1034878/",
   "anchor": "guzman-ott-1976"
  },
  {
   "kind": "history",
   "title": "Psychotropic mushroom meeting at a Washington state park (the PSMS bulletin's \"First Psychotropic Mushroom Foray\")",
   "institution": "Reported by the Puget Sound Mycological Society, Seattle",
   "year": 1976,
   "condition": "Psychotropic mushrooms",
   "status": "Held Halloween weekend 1976; reported December 1976",
   "finding": "The society's bulletin called it \"The First Psychotropic Mushroom Foray\" and reported about 120 attendees; speakers included Gastón Guzmán, Jonathan Ott, R. Gordon Wasson and Lynn Brady of the UW School of Pharmacy.",
   "id": "PSMS bulletin No. 127",
   "url": "https://www.psms.org/sporeprints/SP127.pdf",
   "anchor": "psychotropic-meeting-1976"
  }
 ]
}